Eugenio Di Brino

Economic and organizational impact of implementing Peristeen Plus in the management of neurogenic bowel dysfunction: evidence from Italy

Filippo Rumi, Agostino Fortunato, Michele Basile, Eugenio Di Brino et autres

Introduction: NBD is a chronic condition in people with spinal cord injury, commonly manifesting as constipation and fecal incontinence. TAI is a minimally invasive alternative to conventional management. Peristeen Plus, a TAI device recommended, enables predictable bowel evacuation, reducing symptoms and quality …

it (code pays fourni par la source)

Corrigendum to “Innovation and sustainability in immune-mediated diseases: An Italian multidisciplinary consensus across gastroenterology, dermatology, and rheumatology” [Digestive and Liver Disease 58 (2026) 1051-1060]

Franco Scaldaferri, Federica Di Vincenzo, Gennaro Marco Falco, Federico Lazzaro et autres

it, lb (code pays fourni par la source)

Extension of the mammographic screening programme in Italy: cost-benefit analysis of early diagnosis in the 45–49 and 70–74 age groups

Eugenio Di Brino, Elena Maria Calosci, Michele Basile, Filippo Rumi et autres

Extending Italy's mammography screening programme to women aged 45-49 and 70-74 could markedly improve breast-cancer prevention, lowering mortality and optimizing healthcare resources. Using a decision-tree model based on national epidemiological data, we compared the current screening coverage scenario, characterized by a partial …

it (code pays fourni par la source)

Innovation and sustainability in immune-mediated diseases: An Italian multidisciplinary consensus across gastroenterology, dermatology, and rheumatology

Franco Scaldaferri, F Di Vincenzo, Gennaro Marco Falco, Federico Lazzaro et autres

BACKGROUND: Advanced therapies (ADTs) have transformed the management of chronic immune-mediated inflammatory diseases (IMIDs) across gastroenterology, dermatology, and rheumatology. Their growing use pressures universal, regionalized systems such as the Italian National Health System, challenging sustainability, equitable access, and integration of innovation. To …

it, lb (code pays fourni par la source)

Cost-effectiveness analysis of lorlatinib as first-line treatment for anaplastic lymphoma kinase (ALK)-positive non–small cell lung cancer in Italy

Ilaria Valentini, Filippo Rumi, Eugenio Di Brino, Alessandra Bearz et autres

BACKGROUND: Lorlatinib is a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) with high central nervous system penetration and activity against resistance mutations. Although its clinical efficacy as first-line treatment for ALK-positive advanced non-small cell lung cancer (NSCLC) has been demonstrated, …

it, us (code pays fourni par la source)

Cost-effectiveness analysis of lorlatinib as first-line treatment for anaplastic lymphoma kinase (ALK)-positive non–small cell lung cancer in Italy

Ilaria Valentini, Filippo Rumi, Eugenio Di Brino, Alessandra Bearz et autres

Lorlatinib is a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) with high central nervous system penetration and activity against resistance mutations. Although its clinical efficacy as first-line treatment for ALK-positive advanced non–small cell lung cancer (NSCLC) has been demonstrated, its …

Cost-effectiveness analysis of lorlatinib as first-line treatment for anaplastic lymphoma kinase (ALK)-positive non–small cell lung cancer in Italy

Ilaria Valentini, Filippo Rumi, Eugenio Di Brino, Alessandra Bearz et autres

Lorlatinib is a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) with high central nervous system penetration and activity against resistance mutations. Although its clinical efficacy as first-line treatment for ALK-positive advanced non–small cell lung cancer (NSCLC) has been demonstrated, its …

Impact of biosimilars on the costs of advanced therapies for inflammatory bowel diseases: a population-based study in Italy

A Tursi, Walter Elisei, Annamaria Pia Terlizzi, N. Antonino et autres

OBJECTIVE: The use of advanced therapies (biologics and small molecules) for treating inflammatory bowel diseases (IBD) has increased in recent years. We aimed to evaluate the incidence and prevalence of IBD in an Italian province (Barletta-Andria-Trani), the rate of IBD patients treated …

us, it, lb, gb (code pays fourni par la source)

Cooperation among stakeholders for the sustainability of the new pharmaceutical paradigm in Italy

Valentina Drago, Eugenio Di Brino, Roberta Laurita, Filippo Rumi et autres

The XXIII National Conference on Pharmaceuticals, held in Catania on February 27-28, 2025, represented a key event for multidisciplinary and cross-sectoral dialogue on the pharmaceutical governance in Italy, with a particular focus on stakeholders’ cooperation. Structured around a plenary session and four …

it, us (code pays fourni par la source)

Erratum in: Economic evaluation of distribution modalities for ostomy and incontinence medical devices within the Italian healthcare context

Agostino Fortunato, M Basile, D. Antonini, Eugenio Di Brino et autres

[This corrects the article DOI: 10.33393/grhta.2026.3606.].

it (code pays fourni par la source)

Economic evaluation of distribution modalities for ostomy and incontinence medical devices within the italian healthcare context

Agostino Fortunato, Michele Basile, Debora Antonini, Eugenio Di Brino et autres

Introduction: The clinical management of ostomy and urinary incontinence poses a substantial challenge forhealthcare systems and patients, as it necessitates the provision of specialized medical devices. In Italy, thesedevices are distributed through multiple distribution modalities.Methods: This study aims to update a previous …

it (code pays fourni par la source)

Clinical and economic burden of urinary tract infections in patients with spinal cord injury and multiple sclerosis in Italy

Filippo Rumi, Agostino Fortunato, Eugenio Di Brino, Michele Basile et autres

Introduction: Urinary tract infections (UTIs) are common complications in patients with spinal cord injuries (SCI)and multiple sclerosis (MS), especially those using intermittent catheterization (IC) for neurogenic bladder management. These infections impact quality of life and place a burden on healthcare systems. This …

it (code pays fourni par la source)